Histomorphologic Observations for Cynomolgus Monkeys after Subchronic Subcutaneous Injection of Recombinant Human Interleukin-4

Abstract

Recombinant human interleukin-4 (rhuIL-4) is a candidate for the treatment of refractory cancer based on its potential to enhance the function of the immune system. Total daily dosages of 0 (placebo control), 1,5, or 25 μg/kg of rhuIL-4 were given as divided (b.i.d.) subcutaneous dosages to male and female cynomolgus monkeys (5/sex/group) for 1 month followed by a 2-week recovery. Histomorphologic evaluation of 3/sex/group at 1 month revealed vascular lesions, granulocytic hyperplasia, and seminiferous tubular atrophy attributed to treatment with rhuIL-4. Dosage-dependent proliferative and inflammatory vascular lesions with eosinophil infiltration affected principally the arterial tree. After 2 weeks of recovery, these lesions, including chronic endarteritis and chronic and/or obliterative arteritis, occurred with an overall lower incidence, and were not observed for monkeys from the 1.0 μg/kg/day group. Granulocytic hyperplasia in bone marrow observed for monkeys from all groups given rhuIL-4 at 1 month was not present after 2 weeks of recovery. Seminiferous tubular atrophy was observed for monkeys from the 5 and 25 μg/kg/day groups at 1 month and after 2 weeks of recovery.

Keywords

Arteritis eosinophil infiltration smooth muscle cell proliferation granulopoiesis lymphoid depletion seminiferous tubular atrophy

References

1. Acres RB , Widmer MB , Grabstein KH , and Gillis S (1987). Regulation of human T-cell proliferation and CTL development by human recombinant interleu-kin-4. Ann. NY Acad. Sci. 532: 1–7.

2. Amann RP (1986). Detection of alterations in testicular and epididymal function in laboratory animals. Environ. Health Perspecl. 70: 149–158.

3. Anderson TD , Hayes TJ , Gately MK , Bontempo JM , Stem LL , and Truitt GA (1988). Toxicity of human recombinant interleukin-2 in the mouse is mediated by interleukin-activated lymphocytes. Lab. Invest. 59: 598–612.

4. Bishop MB and Lansing LS (1982). The spleen: A correlative overview of normal and pathologic anatomy. Hum. Pathol. 13: 334–342.

5. Brown M , Hu-Li J , and Paul WE (1988). IL-4/B cell stimulatory factor 1 stimulates T-cell growth by an IL-2-independent mechanism. J. Immunol. 141: 504–511.

6. Damle NK , Doyle LV , Bender JR , and Bradley EC (1987). Interleukin 2-activated human lymphocytes exhibit enhanced adhesion to normal vascular endothelial cells and cause their lysis. J. Immunol. 138: 1779–1785.

7. Jonasson L , Hohn J , and Hansson GK (1988). Cyclosporin A inhibits smooth muscle proliferation in the vascular response to injury. Proc. Natl. Acad. Sci. 85: 2303–2306.

8. Kawakami Y , Rosenberg SA , and Lotze MT (1988). Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma. J. Exp. Med. 168: 2183–2191.

9. Kovacs EJ (1991). Fibrogenic cytokines: The role of immune mediators in the development of scar tissue. Immunol. Today 12: 17–23.

10.

10. Mitchell LC , Davis LS , and Lipsky PE (1989). Promotion of human T lymphocyte proliferation by IL-4. J. Immunol. 142: 1548–1557.

11.

11. Rennick D , Yang G , Muller-Sieburg C , Smith C , Arai N , Takabe Y , and Gemmell L (1987). Interleukin 4 (B-cell stimulatory factor 1) can enhance or antagonize the factor-dependent growth of hemopoietic progenitor cells. Immunology 84: 6889–6893.

12.

12. Shimokado K , Raines EW , Madtes DK , Barrett TB , Benditt EP , and Ross R (1985). A significant part of macrophage-derived growth factor consists of at least two forms of PDGF. Cell 43: 277–286.

13.

13. Thornhill MH , Kyan-Aung U , and Haskard DD (1990). IL-4 increases human endothelial cell adhesiveness for T cells but not for neutrophils. J. Immunol. 144: 3060–3065.

14.

14. Vellenga E , deWolf JThM , Beentjes JAM , Esselink MT , Smit JW , and Halie MR (1990). Divergent effects of interleukin-4 (IL-4) on the granulocyte colony-stimulating factor and IL-3-supported myeloid colony formation from normal and leukemic bone marrow cells. Blood 75: 633–637.

15.

15. Warren DJ and Sanderson CJ (1985). Production of a T-cell hybrid producing a lymphokine stimulating eosinophil differentiation. Immunology 54: 615–623.